Follow Forum_Psych on Twitter
Search
 
 

Display results as :
 


Rechercher Advanced Search

Statistics
We have 222 registered users
The newest registered user is raheelmemon

Our users have posted a total of 1140 messages in 613 subjects
If you are seeing this, you have attempted to link to the UpToDate widget but are experiencing a problem. Please visit UpToDate for more information.
Share

Clonazepam in treatment of Panic Disorder with or without agoraphobia: Dose-Response Study of Efficacy, Safety, and Discontinuance

View previous topic View next topic Go down

Clonazepam in treatment of Panic Disorder with or without agoraphobia: Dose-Response Study of Efficacy, Safety, and Discontinuance

Post  Admin on Sat Sep 24, 2011 5:43 pm

Clonazepam in treatment of Panic Disorder with or without agoraphobia: Dose-Response Study of Efficacy, Safety, and Discontinuance

Rosenbaum JF, Moroz G, Bowden CL. J Clin Psychopharmacol. 1997 Oct;17(5):390-400.


413 patients were randomly assigned to receive placebo or one of five fixed daily doses of clonazepam (0.5 mg, 1.0 mg, 2.0 mg, 3.0 mg, and 4.0 mg).
After 3 weeks of dose escalation, the fixed dose was given for 6 weeks (the dose-maintenance phase) and then was tapered during a 7-week discontinuance phase.

Results:
- The minimum effective dosage, as determined by the Williams' test, was 1.0 mg daily. Dose-response analysis showed that daily dosages of 1.0 mg and higher were equally efficacious in reducing the number of panic attacks.
- All treatments were well tolerated.
- Somnolence and ataxia were reported more often by patients in the 3.0- and 4.0-mg groups;
- depression, dizziness, fatigue, and irritability, although not showing dose-relatedness, were reported by more patients taking clonazepam than placebo.
- During the discontinuance phase, most patients worsened from their condition at the end of the dose-maintenance phase but did not revert to that at baseline.
- Daily doses of 1.0 to 2.0 mg of clonazepam offered the best balance of therapeutic benefit and tolerability.

Read the full study here: Journal of Clinical Psychopharmacology


*****************
Click on to post your comments
avatar
Admin
Admin
Admin

Posts : 948
Points : 2102
Reputation : 0
Join date : 2011-02-19
Location : Philadelphia

http://psychiatry.find-forum.net

Back to top Go down

View previous topic View next topic Back to top

- Similar topics

 
Permissions in this forum:
You cannot reply to topics in this forum